Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2007
01/25/2007WO2007011284A1 Therapeutic agents
01/25/2007WO2007011232A2 Lipid lowering agents for increasing bmd
01/25/2007WO2007011231A2 Use of compounds comprising fatty acid entities
01/25/2007WO2007011072A1 Premature ovulation preventive agent
01/25/2007WO2007011066A1 Fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, atp production promoter, melanin formation inhibitor, and agent for external application to the skin
01/25/2007WO2007011056A1 Pyrazole compounds and thrombopoietin receptor activators
01/25/2007WO2007011018A1 Rapidly disintegratable oral tablet
01/25/2007WO2007010999A1 Animal in which lipid metabolism and sugar metabolism are modified by krap gene mutation, modification method and modifying agent
01/25/2007WO2007010976A1 Body weight gain inhibitory composition comprising d-psicose and use thereof
01/25/2007WO2007010975A1 Use of psicose in agent for prevention of the increase in blood d-fructose level
01/25/2007WO2007010974A1 Use of antihypergycemic effect of d-allose
01/25/2007WO2007010973A1 Utilization of anti-neuropathic pain effect of d-allose and d-psicose
01/25/2007WO2007010965A1 Azaindole derivative having pgd2 receptor antagonistic activity
01/25/2007WO2007010964A1 Indole derivative having pgd2 receptor antagonist activity
01/25/2007WO2007010946A1 Synovial cell proliferation inhibitor
01/25/2007WO2007010911A1 Agent for relieving wound and promoting wound recovery
01/25/2007WO2007010910A1 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl]-methyl piperidine p-toluenesulfonate or crystal thereof
01/25/2007WO2007010885A1 Substituted propanamide derivative and pharmaceutical composition containing the same
01/25/2007WO2007010853A1 Method for control of electroporation apparatus
01/25/2007WO2007010847A1 Sustained release preparation
01/25/2007WO2007010846A1 Preparation having gastric residence capability
01/25/2007WO2007010723A1 Tryptophan derivative and use thereof
01/25/2007WO2007010628A1 Prophylactic/therapeutic agent for cancer
01/25/2007WO2007010557A2 Process for the preparation of highly pure ropinirole
01/25/2007WO2007010554A2 A system for mounting feeder over a rotating die-table of tablet press and method thereof
01/25/2007WO2007010546A1 Compounds for treatment of lipase-mediated diseases
01/25/2007WO2007010515A1 Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation
01/25/2007WO2007010504A2 Acid addition salts of isoindoles acting as adrenergic receptor antagonists
01/25/2007WO2007010501A2 A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
01/25/2007WO2007010499A2 Derivatives of monosaccharides for the treatment of copd and allergic rhinitis
01/25/2007WO2007010390A1 Indazolecarboxamide derivatives as 5ht4 receptor agonists
01/25/2007WO2007010383A1 Novel heterocyclidene acetamide derivative
01/25/2007WO2007010337A2 Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
01/25/2007WO2007010312A2 Use of mmp inhibitors for the preparation of pharmaceutical compositions of cardioprotective effect
01/25/2007WO2007010307A1 Antineoplastic compounds
01/25/2007WO2007010283A1 Serine beta-lactamase-like / d-ala carboxypeptidase-like protein
01/25/2007WO2007010275A1 Novel epilepsy treatment
01/25/2007WO2007010266A1 Pyrrolidine compositions
01/25/2007WO2007010242A1 Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
01/25/2007WO2007010235A1 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide
01/25/2007WO2007010216A1 Lycopene formulations for the treatment of atherosclerotic conditions
01/25/2007WO2007010144A1 N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and use thereof
01/25/2007WO2007010084A2 Immunostimulatory oligo- and polysaccharides and uses thereof
01/25/2007WO2007010044A1 3-indolylmethylene derivatives with cytostatic action
01/25/2007WO2007010032A2 Intermolecular association complex of a carrier, preferably an n-alkylamino -1-desoxylactitol and of an active ingredient
01/25/2007WO2007010013A2 Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases
01/25/2007WO2007010012A2 Combination of a pyrimidylaminobenzamide and an mtor kinase inhibitor
01/25/2007WO2007009959A1 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders
01/25/2007WO2007009913A1 Pyridazinone derivatives as thyroid hormone receptor agonists
01/25/2007WO2007009911A1 PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
01/25/2007WO2007009906A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists
01/25/2007WO2007009898A1 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
01/25/2007WO2007009897A1 Biologically active compounds obtainable from sorangium cellulosum
01/25/2007WO2007009883A1 Novel heteroaryl fused cyclic amines
01/25/2007WO2007009819A1 Acylglycerophospholipids for treating symptoms concomitant with cancer
01/25/2007WO2007009806A2 Solid dosage formulations of narcotic drugs having improved buccal adsorption
01/25/2007WO2007009801A2 Oral, quickly disintegrating film, which cannot be spit out, for a neuroleptic drug
01/25/2007WO2007009800A2 Oral, quickly disintegrating film, which cannot be spit out, for an antiemetic or antimigraine agent
01/25/2007WO2007009799A1 Amino acid salts of rosiglitazone
01/25/2007WO2007009794A1 HCl POLYMORPHS OF 3 -(2-(DIMETHYLAMINO)METHYL(CYCLOHEX-1-YL))PHENOL
01/25/2007WO2007009793A1 Salt of fumaric acid and 3-(2-dimethylamino)methyl(cyclohex-1-yl))phenol and its crystalline forms
01/25/2007WO2007009792A1 3-(2-(dimethylamino)methyl(cyclohex-1-yl))phenol maleate and its crystalline forms
01/25/2007WO2007009788A1 A process and composition for making olanzapine form (i)
01/25/2007WO2007009778A1 Piperidine carboxamide derivate suitable as tachykinin receptor antagonist
01/25/2007WO2007009777A1 Chemical compounds
01/25/2007WO2007009776A1 Process for preparing uronic acid oligosaccharides by extrusion
01/25/2007WO2007009774A1 Benzimidazole derivatives for treatment of inflammatory diseases
01/25/2007WO2007009773A1 Pyrazolo[1.5-a]pyrimidin-7-yl amine derivatives as protein kinase inhibitors
01/25/2007WO2007009772A1 Thiocolchicoside analogues with myorelaxant and anti-inflammatory activity
01/25/2007WO2007009769A1 Oral contraception with trimegestone
01/25/2007WO2007009757A1 Purine derivatives as agonists of the adenosine a2a receptor
01/25/2007WO2007009742A1 Low-glycemic mixtures
01/25/2007WO2007009741A1 Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists
01/25/2007WO2007009739A1 Compounds
01/25/2007WO2007009734A2 Combination preparation, particularly for treating prostate cancer
01/25/2007WO2007009724A2 Cycloalkane-substituted pyrazoline derivatives, their preparation and use as medicaments
01/25/2007WO2007009723A2 Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
01/25/2007WO2007009722A1 Octahydropentalene-substituted pyrazoline derivatives, their preparation and use as medicaments
01/25/2007WO2007009721A2 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments
01/25/2007WO2007009720A2 Prodrugs of pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009715A1 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
01/25/2007WO2007009712A1 Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009709A1 Cycloalkane-substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009708A1 Salts of substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009707A2 Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
01/25/2007WO2007009705A1 (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
01/25/2007WO2007009700A2 Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
01/25/2007WO2007009698A1 Combination of pyrazoline type cannabinoid receptor antagonist and statin
01/25/2007WO2007009697A1 Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009696A1 Use of substituted pyrazoline compounds for the preparation of paediatric medicaments
01/25/2007WO2007009695A1 Substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009694A1 Use of substituted pyrazoline compounds for the preparation of medicaments for the treatment of metabolic syndrome
01/25/2007WO2007009693A1 Combination of a substituted pyrazoline compound and a drug used in food-related disorders
01/25/2007WO2007009692A1 Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
01/25/2007WO2007009691A2 Combination of substituted pyrazolines and anti -addictive agent
01/25/2007WO2007009690A1 Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
01/25/2007WO2007009689A1 4,5-dihydr0-1h-pyrazole derivatives, their preparation and use as medicaments
01/25/2007WO2007009688A1 Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as cb1 modulators
01/25/2007WO2007009687A1 Carbonyl substituted pyrazoline compounds, their preparation and use as cb1 receptor modulators
01/25/2007WO2007009683A2 Pharmaceutical formulations of substituted pyrazoline compounds